(33 days)
No
The description focuses on the physical components and mechanical functions of a blood reservoir for extracorporeal circulation. There is no mention of software, algorithms, or data processing that would indicate the use of AI or ML.
No.
The device is a blood storage and processing device used during extracorporeal circulation, post-operative chest drainage, and autotransfusion procedures. While it's used in medical procedures, its primary function is not to directly treat a disease or medical condition but rather to facilitate a medical procedure.
No
The device is described as a hardshell reservoir used to store blood, remove particulates and air bubbles, and facilitate blood return to the patient during and after extracorporeal circulation procedures. Its function is to manage blood flow and quality, not to diagnose medical conditions or provide information for diagnosis.
No
The device description clearly outlines a physical, hardshell reservoir with filters, defoamers, and ports for blood flow, indicating it is a hardware device.
Based on the provided information, this device is not an IVD (In Vitro Diagnostic).
Here's why:
- IVD Definition: In vitro diagnostics are tests performed on samples taken from the human body, such as blood or tissue, to detect diseases, conditions, or infections. They are used to provide information for diagnosis, monitoring, or screening.
- Device Function: The Capiox® Advance Hardshell Reservoir is a device used during and after extracorporeal circulation (like cardiopulmonary bypass). Its primary functions are:
- Storing blood.
- Filtering particulate matter from blood.
- Removing air bubbles from blood.
- Facilitating the return of blood to the patient.
- Lack of Diagnostic Testing: The device does not perform any tests on the blood to diagnose, monitor, or screen for any medical condition. It is a component of a larger medical procedure (extracorporeal circulation) that handles and processes blood physically.
The description clearly outlines its role in managing blood flow and quality during and after surgery, not in analyzing the blood for diagnostic purposes.
N/A
Intended Use / Indications for Use
The Capiox® Advance Hardshell Reservoir is a hardshell reservoir used to store blood during extracorporeal circulation from both the venous line and the cardiotomy line. The reservoir contains filters to remove particulate matter and defoamers to facilitate air bubble removal.
The Hardshell Reservoir is also used for post-operative chest drainage and autotransfusion procedures to aseptically return blood to the patient for blood volume replacement.
The Hardshell Reservoir is also used with the vacuum-assisted venous return technique during cardiopulmonary bypass.
The Hardshell Reservoir contains X-Coating, which is intended to reduce platelet adhesion on the surfaces of the device.
The device may be used for procedures lasting up to 6 hours.
Product codes
DTN, DTP
Device Description
The design of the Capiox® Advance Hardshell Reservoir is comprised of a hardshell casing that serves as a blood containment system within the bypass circuit. The upper portion of the reservoir consists of a hardshell lid assembly that contains the necessary inlet ports and vent ports. It contains a rotatable venous blood inlet port. The total capacity of the reservoir is 4000mL.
The venous section of the reservoir contains a filter for particulate matter removal and a defoamer to facilitate air bubble removal. The cardiotomy section of the reservoir contains a filter for particulate matter removal and a defoamer to facilitate air bubble removal.
Mentions image processing
Not Found
Mentions AI, DNN, or ML
Not Found
Input Imaging Modality
Not Found
Anatomical Site
Not Found
Indicated Patient Age Range
Not Found
Intended User / Care Setting
Not Found
Description of the training set, sample size, data source, and annotation protocol
Not Found
Description of the test set, sample size, data source, and annotation protocol
Not Found
Summary of Performance Studies
Substantial equivalence is demonstrated with the following in-vitro performance evaluations:
- Air Handling Performance
- Hemolysis
- Venous Filter Dynamic Hold Up and/or Pressure Drop
- Vacuum Testing (Product Integrity, Large Venous Port-O-Ring Seal)
- Burst, Leak, Circulation, and/or Pull Testing to Evaluate Venous Port and Tubing Connection Integrity
- Pre-Connect Evaluation
- Package Testing
Key Metrics
Not Found
Predicate Device(s)
Reference Device(s)
Predetermined Change Control Plan (PCCP) - All Relevant Information
Not Found
§ 870.4400 Cardiopulmonary bypass blood reservoir.
(a)
Identification. A cardiopulmonary bypass blood reservoir is a device used in conjunction with short-term extracorporeal circulation devices to hold a reserve supply of blood in the bypass circulation.(b)
Classification. Class II (special controls), except that a reservoir that contains a defoamer or filter is classified into the same class as the defoamer or filter. The device, when it is a cardiopulmonary bypass blood reservoir that does not contain defoamers or blood filters, is exempt from the premarket notification procedures in subpart E of part 807 of this chapter subject to the limitations in § 870.9.
0
Image /page/0/Picture/1 description: The image shows the logo for the U.S. Department of Health & Human Services. The logo features a stylized representation of three human profiles facing right, layered on top of each other. The profiles are black and have a flowing, abstract design. The logo is surrounded by a circular border with the text "DEPARTMENT OF HEALTH & HUMAN SERVICES - USA" in black, uppercase letters.
Food and Drug Administration 10903 New Hampshire Avenue Document Control Center - WO66-G609 Silver Spring, MD 20993-0002
December 02, 2015
Terumo Cardiovascular Systems Corporation Tierra Brown Regulatory Affairs Specialist 125 Blue Ball Road Elkton, Maryland 21921
Re: K153143
Trade/Device Name: Capiox Advance Hardshell Reservoir Regulation Number: 21 CFR 870.4400 Regulation Name: Cardiopulmonary Bypass Blood Reservoir Regulatory Class: Class II Product Code: DTN, DTP Dated: October 22, 2015 Received: October 30, 2015
Dear Tierra Brown:
We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food. Drug. and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you, however, that device labeling must be truthful and not misleading.
If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.
Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); medical device reporting of medical devicerelated adverse events) (21 CFR 803); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.
1
If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please contact the Division of Industry and Consumer Education at its toll-free number (800) 638-2041 or (301) 796-7100 or at its Internet address
http://www.fda.gov/MedicalDevices/ResourcesforYou/Industry/default.htm. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to
http://www.fda.gov/MedicalDevices/Safety/ReportaProblem/default.htm for the CDRH's Office of Surveillance and Biometrics/Division of Postmarket Surveillance.
You may obtain other general information on your responsibilities under the Act from the Division of Industry and Consumer Education at its toll-free number (800) 638-2041 or (301) 796-7100 or at its Internet address
http://www.fda.gov/MedicalDevices/ResourcesforYou/Industry/default.htm.
Sincerely yours,
M.A. Hillebrand
for Bram D. Zuckerman, M.D. Director Division of Cardiovascular Devices Office of Device Evaluation Center for Devices and Radiological Health
Enclosure
2
piox Advance Hardshell Reser U CLION 4 - Indications for U TERUM
10(li) Number (f known); Unknown at time of Submission
Device Name: Capiones Advance Hardshall Reservo
indications for Use:
സ്വന്തമാക്കും വിശ്വാസ്ത്രാക്കു വിവേശം നിന്നും നിന്നുവെന്നും അവന്നും കാവന്യത്.
പിരുന്നും വിവ്യ നിരക്കു വിമ്പേ ബന്ധം നിന്നും നിന്നുവെന്നും അവന്മാനും നിന്നും വല
ുന്നു. പിന്നു ന
olsunan bir əsasən qalınmışdır. Əhli olan qalınmışı ilk olan çıxır. Bu mərkəzi ilə bir mərkəzi ilə bir mərkəzi ilə bir mə
isquinonary bypasss Hardshell Reservoir is also used with the vacuum-assisted venous return technique during
surfaces of the device no noised bel a service of bebruari si doine si instrument of Services Nellebresses in
he is nay be used for proceedures lasting up to 6 hours
Prescription Use 21 CFR 801 Subpart D XX AO
as and results in the program in the first of O
SA NEEDED) F
oncurrence of CDRRH, Office of Device Evaluation (ODE
21
3
TERUMO® SECTION 5 – 510(k) Summary Capiox® Advance Hardshell Reservoir
| Submitter Information | |
|---|---|
| Date of Preparation | October 22, 2015 |
| Name | Terumo Cardiovascular Systems Corporation |
| Address | 125 Blue Ball Road |
| Elkton, MD 21921 | |
| Establishment Registration Number | 1124841 |
| Name of Contact Person | Tierra A. Brown, MSRA, RAC |
| Contact Person's Title | Regulatory Affairs Specialist |
| Phone Number | (800) 262-3304 (x7021) |
| Fax Number | 410-392-7171 |
| tierra.brown@terumomedical.com |
| Device Information | |
|---|---|
| Device Classification Type | Cardiopulmonary Bypass Blood Reservoir (Code DTN) |
| Cardiopulmonary Bypass Defoamer (Code DTP) | |
| Device Common Name | Blood Reservoir |
| Defoamer | |
| Device Trade Name | Capiox® Advance Hardshell Reservoir |
| Predicate Device | Capiox® RX Hardshell Reservoir; Cleared by FDA with |
| K130359 | |
| Classification Regulation | Cardiopulmonary Bypass Reservoir 21 CFR § 870.4400 |
| Cardiopulmonary Bypass Defoamer 21 CFR § 870.4230 | |
| Device Risk Classification | Cardiopulmonary Bypass Reservoir - Class II |
| Cardiopulmonary Bypass Defoamer – Class II | |
| Reason for 510(k) Submission | Modification to Hardshell Reservoir |
| Substantial Equivalence Statement | The device submitted in this 510(k) maintains |
| characteristics that are substantially equivalent in | |
| intended use, design, technology/principles of operation, | |
| materials and specifications to the predicate device. |
4
Capiox® Advance Hardshell Reservoir
Intended Use:
The intended use remains the same as the intended use for the predicate device cleared with submission K130359. There have been no changes to the indications or intended use of the subject device as a result of the modifications.
The Capiox® Advance Hardshell Reservoir is a hardshell reservoir used to store blood during extracorporeal circulation from both the venous line and the cardiotomy line. The reservoir contains filters to remove particulate matter and defoamers to facilitate air bubble removal.
The Hardshell Reservoir is also used for post-operative chest drainage and autotransfusion procedures to aseptically return blood to the patient for blood volume replacement.
The Hardshell Reservoir is also used with the vacuum-assisted venous return technique during cardiopulmonary bypass.
The Hardshell Reservoir contains X-Coating, which is intended to reduce platelet adhesion on the surfaces of the device.
The device may be used for procedures lasting up to 6 hours.
Principles of Operation and Technology:
The principles of operation and technological characteristics remain the same as that of the predicate device cleared with submission K130359. There have been no changes to the fundamental scientific technology of the subject device.
The Capiox® Advance Hardshell Reservoir device and the predicate Capiox® RX Hardshell Reservoir device are both used as a blood storage devices during and after cardiopulmonary bypass procedures. Venous blood enters the reservoir via gravity, or by way of external vacuum that may be applied to the reservoir.
Venous blood that is drawn from the patient enters the device via the venous blood inlet port. The blood passes through a defoamer to remove air bubbles from the blood and through a filter to remove particulates from the blood.
Blood may also be suctioned into the reservoir from the cardiotomy field. This blood enters the device through the cardiotomy blood suction ports. The blood passes through a defoamer to remove air bubbles from the blood and through a filter to remove particulates from the blood.
Blood exits the device via gravity through the blood outlet port and is subsequently pumped through the remainder of the cardiopulmonary bypass circuit.
Design and Materials:
The design of the Capiox® Advance Hardshell Reservoir is comprised of a hardshell casing that serves as a blood containment system within the bypass circuit. The upper portion of the
5
SECTION 5-510(k) Summary Capiox® Advance Hardshell Reservoir
reservoir consists of a hardshell lid assembly that contains the necessary inlet ports and vent ports. It contains a rotatable venous blood inlet port. The total capacity of the reservoir is 4000mL.
The venous section of the reservoir contains a filter for particulate matter removal and a defoamer to facilitate air bubble removal. The cardiotomy section of the reservoir contains a filter for particulate matter removal and a defoamer to facilitate air bubble removal.
Differences in the design of the two Reservoirs are as follows:
- The design of the Capiox® Advance Hardshell Reservoir device will include a curved ● venous inlet port and flared venous inlet drop tubes. The design of the predicate Capiox® RX Hardshell Reservoir device has an angled venous inlet port and straight venous inlet drop tubes. The intent of the curved venous inlet port is to improve air handling performance of the port. A curved design is more conducive to smooth flow than an angled design. The intent of the flared venous inlet drop tubes modification is to help minimize air emboli generation in the venous section of the reservoir.
- o The Capiox® Advance Hardshell Reservoir device has a full-length graduated side scale label (decal). The predicate Capiox® RX Hardshell Reservoir device has a half-length graduated side scale label (decal). The full-length graduated side scale label (decal) enhancement offers greater visibility of blood volume during cardiopulmonary bypass.
- . The Capiox® Advance Hardshell Reservoir device has a minimum operating volume of The predicate Capiox® RX Hardshell Reservoir device has a minimum 150mL. operating volume of 200mL. The minimum operating volume is lowered to 150mL to facilitate lower blood volumes during cardiopulmonary bypass.
Difference in the materials of the two Reservoirs are as follows:
The materials used in the construction of the Capiox® Advance Hardshell Reservoir include, but are not limited to, nylon, polycarbonate, silicone, polyvinyl chloride, polyurethane, polyester, polypropylene, polymethyl methacrylate, polyhydroxyethyl methacrylate, polyethylene, and X-Coating™. PVC tubing with TOTM plasticizer has been cleared for use with Terumo's FX15 Advance Oxygenator with Integrated Filter and Hardshell Reservoir, K151389.
- The material used in the construction of the Capiox® Advance Hardshell Reservoir o device's venous inlet drop tubes and auxiliary tubing (blood-contacting) will be PVC tubing with Tris-(2-Ethylhexyl) Trimellitate, identified as TOTM plasticizer'. The material used in the construction of the predicate Capiox® RX Hardshell Reservoir device's venous inlet drop tubes and auxiliary tubing (blood-contacting) is PVC tubing with Di-(2-ethylhexyhl) phthalate, identified as DEHP plasticizer.
- . The intent of the PVC tubing plasticizer change to TOTM plasticizer is to address growing potential safety concerns associated with DEHP and to address increasing concerns related to the use of DEHP.
Terumo Cardiovascular Systems concludes that the differences between the subject device and the predicate device do not affect the intended use of the device nor do they affect safety and effectiveness of the device when used as labeled.
1 PVC tubing with Tris-(2-Ethylhexyl) Trimellitate, identified as TOTM plasticizer, is used with Terumo's Capiox® FX15 Advance Oxygenator with Integrated Filter and Hardshell Reservoir, K151389.
6
Capiox® Advance Hardshell Reservoir
Performance Evaluations:
Clinical studies involving patients are not necessary to demonstrate substantial equivalence of the Capiox® Advance Hardshell Reservoir to the predicate device. Substantial equivalence is demonstrated with the following in-vitro performance evaluations:
- Air Handling Performance ●
- Hemolysis .
- Venous Filter Dynamic Hold Up and/or Pressure Drop .
- Vacuum Testing (Product Integrity, Large Venous Port-O-Ring Seal) .
- Burst, Leak, Circulation, and/or Pull Testing to Evaluate Venous Port and Tubing ● Connection Integrity
- Pre-Connect Evaluation ●
- . Package Testing
Substantial Equivalence Comparison:
In demonstrating substantial equivalence of the Capiox® Advance Hardshell Reservoir to the predicate Capiox® RX Hardshell Reservoir, Terumo has considered the following aspects to ensure equivalence between the predicate and the subject devices:
- Intended use .
- . Target Population
- Duration of use ●
- Product labeling .
- Product design ●
- Materials .
- Principles of Operation and Technology ●
- Device Performance .
Substantial Equivalence Statement:
The Capiox® Advance Hardshell Reservoir is substantially equivalent to the predicate Capiox® RX Hardshell Reservoir in intended use, duration of use, design, materials, principles of operation and technology, and performance and specifications. Any noted differences between the subject device and the predicate device do not raise new issues of safety and/or effectiveness.
Conclusion:
Based upon the comparative studies and analyses, Terumo Cardiovascular Systems concludes that the Capiox® Advance Hardshell Reservoir is substantially equivalent in intended use, duration of use, design, materials, principles of operation and technology, and performance and specifications to the predicate Capiox® RX Hardshell Reservoir. It is further concluded that any recognized differences noted during the assessments do not raise new issues of patient/user safety or product effectiveness.